Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria: Patients who have been diagnosed with type 2 diabetes mellitus within the previous 12 months. Glycated hemoglobin (HbA1c) between 7% and 9%. Body mass index ≥ 25 kg/m2 Exclusion Criteria: Pregnant or nursing women. Type 1 diabetes mellitus. Liver disease (alanine aminotransferase > 3 upper normal limit). Kidney disease (estimated glomerular filtration rate < 60 ml/min/1.73 m2). Inflammatory bowel diseases History of allergy and/or adverse reactions to the drugs used in the study.
Sites / Locations
- Faculty of medicine, Tanta UniversityRecruiting
- Faculty of Medicine, Menoufia UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
No Intervention
Active Comparator
Group 1
Group 2
44 diabetic patients receiving dual treatment with metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin)
44 diabetic patients who will receive ursodeoxycholic acid 500 mg orally twice daily in addition to dual treatment with metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin)